ortus 05 sc
nichino europe co. ltd_x000d_ vision park, pioneer court, cb24 9pt cambridge, wielka brytania - fenpiroksymat - fenpiroksymat - 51,2 g - akarycyd
zorac 500 mcg/g (0,05%) Żel
allergan pharmaceuticals international ltd. clonshaugh business & technology park - tazarotenum - Żel - 500 mcg/g (0,05%)
zorac 1 mg/g (0,1%) Żel
allergan pharmaceuticals international ltd. clonshaugh business & technology park - tazarotenum - Żel - 1 mg/g (0,1%)
tessie
orion corporation - tasipimidine sulfate - other hypnotics and sedatives - psy - alleviation of situational anxiety and fear in dogs triggered by e. travel, noise, owner departure, veterinary visits.
cobalt
sharda cropchem ltd._x000d_ prime business park dashrathlal joshi road, vile parle (west), 400 056 mumbai, republika indii - boskalid - 267 g, _x000d_ piraklostrobina - 67 g - fungicyd
society
sharda cropchem ltd._x000d_ prime business park dashrathlal joshi road, vile parle (west), 400 056 mumbai, republika indii - cyprodynil - 375 g, _x000d_ fludioksonil - 250 g - fungicyd
azuba
sharda cropchem ltd. prime business park dashrathlal joshi road, vile parle (west), 400 056 mumbai, republika indii - azoksystrobina - 250 g - fungicyd
spinraza
biogen netherlands b.v. - sól sodowa nusinersen - zanik mięśni, kręgosłup - inne leki na układ nerwowy - spinraza jest wskazany w leczeniu 5-rdzeniowego zaniku mięśni.
evrysdi
roche registration gmbh - risdiplam - zanik mięśni, kręgosłup - inne leki stosowane w zaburzeniach układu mięśniowo-szkieletowego - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.
locametz
novartis europharm limited - gozetotide - obrazowanie radionuklidami - diagnostyczne radiofarmaceutyki - ten produkt leczniczy jest przeznaczony wyłącznie do celów diagnostycznych. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.